Patents by Inventor Elena Feinstein

Elena Feinstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
    Patent number: 8404654
    Abstract: The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: March 26, 2013
    Assignee: Quark Pharmaceuticals, Inc.
    Inventor: Elena Feinstein
  • RETINOID-LIPOSOMES FOR ENHANCING MODULATION OF HSP47 EXPRESSION
    Publication number: 20130071478
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
    Type: Application
    Filed: June 8, 2012
    Publication date: March 21, 2013
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • RETINOID-LIPOSOMES FOR TREATING FIBROSIS
    Publication number: 20130071467
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis.
    Type: Application
    Filed: June 8, 2012
    Publication date: March 21, 2013
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS
    Publication number: 20130035368
    Abstract: The invention relates to siRNA compounds comprising one non-nucleotide moiety covalently attached to at least one of the sense or antisense strands to down-regulate the expression of human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the target genes and/or symptoms associated with such diseases or conditions.
    Type: Application
    Filed: January 6, 2011
    Publication date: February 7, 2013
    Inventors: Sharon Avkin-Nachum, Elena Feinstein
  • MODULATION OF TIMP1 AND TIMP2 EXPRESSION
    Publication number: 20130030034
    Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly of tissue inhibitor of metalloproteinase 1 and of tissue inhibitor of metalloproteinase 2 (TIMP1 and TIMP2, respectively). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding TIMP1 and TIMP2, for example, the gene encoding human TIMP1 and TIMP2. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with TIMP1 and TIMP2 including fibrotic diseases and disorders including liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.
    Type: Application
    Filed: September 27, 2011
    Publication date: January 31, 2013
    Inventors: Yoshiro Niitsu, Hirokazu Takahashi, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
  • Tandem siRNAS
    Patent number: 8362229
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: January 29, 2013
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Huseyin Aygun, Elena Feinstein
  • Screening systems utilizing RTP801
    Patent number: 8344104
    Abstract: RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: January 1, 2013
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roni Wechsler, Igor Mett, Elena Feinstein
  • Therapeutic uses of inhibitors of RTP801
    Patent number: 8309532
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: November 13, 2012
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • METHODS AND COMPOSITIONS FOR TREATING DISEASES, DISORDERS OR INJURY OF THE CNS
    Publication number: 20120252875
    Abstract: The present invention relates to non-invasive methods for treating diseases, disorders and injury to the central nervous system (CNS), and in particular to otic compositions and to methods of use thereof.
    Type: Application
    Filed: December 9, 2010
    Publication date: October 4, 2012
    Inventors: Elena Feinstein, Igor Spivak, Evgenia Alpert, Ron Lahav
  • METHODS FOR DELIVERY OF SIRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM
    Publication number: 20120252874
    Abstract: The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver an siRNA compound locally, directly and without the need for transduction vehicles and formulations in effective doses to the injured spinal cord to promote recovery of CNS function and or attenuation of allodynia.
    Type: Application
    Filed: November 8, 2010
    Publication date: October 4, 2012
    Inventors: Elena Feinstein, Martin Grumet
  • siRNA compounds for inhibiting NRF2
    Patent number: 8278287
    Abstract: The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: October 2, 2012
    Assignee: Quark Pharmaceuticals Inc.
    Inventors: Elena Feinstein, Igor Mett, Hagar Kalinski
  • OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF ALOPECIA, ACUTE RENAL FAILURE AND OTHER DISEASES
    Publication number: 20120184597
    Abstract: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 19, 2012
    Inventors: Elena Feinstein, Daniel Zurr, Shai Ehrlich
  • THERAPEUTIC USES OF INHIBITORS OF RTP801
    Publication number: 20120156208
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.
    Type: Application
    Filed: September 15, 2011
    Publication date: June 21, 2012
    Inventors: Elena Feinstein, Rami Skaliter
  • Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
    Patent number: 8198258
    Abstract: The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: June 12, 2012
    Assignee: Quark Pharmaceuticals Inc.
    Inventors: Orna Mor, Elena Feinstein
  • METHODS FOR TREATING CHRONIC KIDNEY DISEASE
    Publication number: 20120141378
    Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.
    Type: Application
    Filed: June 7, 2010
    Publication date: June 7, 2012
    Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
  • MODULATION OF TIMP1 AND TIMP2 EXPRESSION
    Publication number: 20120142754
    Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly of tissue inhibitor of metalloproteinase 1 and of tissue inhibitor of metalloproteinase 2 (TIMP1 and TIMP2, respectively). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding TIMP1 and TIMP2, for example, the gene encoding human TIMP1 and TIMP2. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with TIMP1 and TIMP2 including fibrotic diseases and disorders including liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.
    Type: Application
    Filed: September 27, 2011
    Publication date: June 7, 2012
    Inventors: Yoshiro Niitsu, Hirokazu Takahashi, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
  • Compositions And Methods Of Inhibiting NADPH Oxidase Expression
    Publication number: 20120136044
    Abstract: The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of a NOX gene selected from the group consisting of NOX4, NOX1, NOX2 (gp91phox, CYBB), NOX5, DUOX2, NOXO1, NOXA1 and NOXA2 (p67phox). The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of various diseases or conditions associated with NOX gene comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
    Type: Application
    Filed: February 7, 2012
    Publication date: May 31, 2012
    Inventors: Hagar Kalinski, Igor Mett, Elena Feinstein
  • COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER AND FIBROTIC DISEASES
    Publication number: 20120114704
    Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically hind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.
    Type: Application
    Filed: March 23, 2010
    Publication date: May 10, 2012
    Inventor: Elena Feinstein
  • THERAPEUTIC USES OF INHIBITORS OF RTP801L
    Publication number: 20120108647
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.
    Type: Application
    Filed: August 25, 2011
    Publication date: May 3, 2012
    Inventors: Elena Feinstein, Igor Mett
  • Methods of treating eye diseases in diabetic patients
    Patent number: 8168607
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: May 1, 2012
    Assignees: Quark Pharmaceuticals Inc., Silence Therapeutics AG
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese